MHLW Warns About Side Effects Before Interferon Treatment Starts
This article was originally published in PharmAsia News
Executive Summary
Starting in April in Japan, hepatitis B and C patients who use the antiviral interferon will be able to receive aid from the government. The program will require patients to pay monthly ¥10,000 to ¥50,000 based on individual income levels and the rest will be covered by the government. As a result, the Ministry of Health, Labor and Welfare estimates that an additional 100,000 patients every year will take interferon treatment. So that patients are aware of potential side effects, MHLW put out a warning March 27. Currently, interferon's label includes warnings about interstitial pneumonitis and suicidal tendencies. MHLW also warns about depression and bleeding due to thrombocytopenia. (Click here for more-Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.